ASCO 2021 | Top news in breast cancer from ASCO 2021
Nadia Harbeck, MD, PhD, Ludwig Maximilians-University of Munich, Munich, Germany reviews findings from the ADAPT and OlympiA trials. It was concluded from the ADAPT trial (NCT01779206) that young pre-menopausal patients with a recurrence score up to 25 who were endocrine responders without chemotherapy had considerably better outcomes than patients who were endocrine non-responders on chemotherapy. This finding is significant from a patient standpoint as it proves chemotherapy can be withheld for nearly half of the young patients. Chemotherapy can be avoided particularly in young women with luminal breast cancer with the incorporation of endocrine responsiveness testing. The OlympiA trial (NCT02032823) evaluated the efficacy of adjuvant olaparib, a PARP inhibitor, in patients with germline BRCA1/2 mutations and high-risk HER2-negative breast cancer. This interview was held at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Nadia Harbeck, MD, PhD, has received honoraria for lectures and/or consulting from Astra Zeneca, Daiichi-Sankyo, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz/Hexal, and Seattle Genetics. Prof. Harbeck is also a co-director of the West German Study Group (WSG).
